Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prediction and clinical utility of a contralateral breast cancer risk model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Daniele Giardiello
  • Ewout W Steyerberg
  • Michael Hauptmann
  • Muriel A Adank
  • Delal Akdeniz
  • Carl Blomqvist
  • Stig E Bojesen
  • Manjeet K Bolla
  • Mariël Brinkhuis
  • Jenny Chang-Claude
  • Kamila Czene
  • Peter Devilee
  • Alison M Dunning
  • Douglas F Easton
  • Diana M Eccles
  • Peter A Fasching
  • Jonine Figueroa
  • Henrik Flyger
  • Montserrat García-Closas
  • Lothar Haeberle
  • Christopher A Haiman
  • Per Hall
  • Ute Hamann
  • John L Hopper
  • Agnes Jager
  • Anna Jakubowska
  • Audrey Jung
  • Renske Keeman
  • Iris Kramer
  • Diether Lambrechts
  • Loic Le Marchand
  • Annika Lindblom
  • Jan Lubiński
  • Mehdi Manoochehri
  • Luigi Mariani
  • Heli Nevanlinna
  • Hester S A Oldenburg
  • Saskia Pelders
  • Paul D P Pharoah
  • Mitul Shah
  • Sabine Siesling
  • Vincent T H B M Smit
  • Melissa C Southey
  • William J Tapper
  • Rob A E M Tollenaar
  • Alexandra J van den Broek
  • Carolien H M van Deurzen
  • Flora E van Leeuwen
  • Chantal van Ongeval
  • Laura J Van't Veer
  • Qin Wang
  • Camilla Wendt
  • Pieter J Westenend
  • Maartje J Hooning
  • Marjanka K Schmidt
Vis graf over relationer

BACKGROUND: Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making.

METHODS: We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility.

RESULTS: In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years, 0.52-0.74; at 10 years, 0.53-0.72). Calibration-in-the-large was -0.13 (95% PI: -1.62-1.37), and the calibration slope was 0.90 (95% PI: 0.73-1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52-0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers.

CONCLUSIONS: We developed a reasonably calibrated model to predict the risk of CBC in women of European-descent; however, prediction accuracy was moderate. Our model shows potential for improved risk counseling, but decision-making regarding contralateral preventive mastectomy, especially in the general breast cancer population where limited information of the mutation status in BRCA1/2 is available, remains challenging.

OriginalsprogEngelsk
TidsskriftBreast Cancer Research
Vol/bind21
Udgave nummer1
Sider (fra-til)144
ISSN1465-542X
DOI
StatusUdgivet - 17 dec. 2019

ID: 59351366